Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs

C. M. Fulkerson, D. Dhawan, D. R. Jones, V. E. Marquez, P. A. Jones, Z. Wang, Q. Wu, J. E. Klaunig, L. M. Fourez, P. L. Bonney, D. W. Knapp

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The purpose of this study was to determine the plasma pharmacokinetics (PK) and toxicity of zebularine, an oral cytidine analog with demethylating activity, in dogs. Plasma zebularine concentrations were determined by HPLC-MS/MS following an oral zebularine dose of 8 or 4 mg kg−1. Plasma zebularine clearance was constant. Mean maximum concentration (Cmax) was 23 ± 4.8 and 8.6 ± 1.4 µM following 8 and 4 mg kg−1, respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 following 8 and 4 mg kg−1, respectively. A single 8 mg kg−1 dose was well tolerated. Daily 4 mg kg−1 treatment in three laboratory dogs resulted in grade 4 neutropenia (n = 3), grade 1 anorexia (n = 2) and grade 1 or 2 dermatologic changes (n = 2). All adverse events resolved with supportive care. A 4 mg kg−1 dose every 21 days was well tolerated. A follow-up dose escalation study is in progress with a lower starting dose.

Original languageEnglish (US)
Pages (from-to)226-236
Number of pages11
JournalVeterinary and Comparative Oncology
Volume15
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

pyrimidin-2-one beta-ribofuranoside
pharmacokinetics
mouth
Pharmacokinetics
Dogs
toxicity
neoplasms
dogs
dosage
Neoplasms
Cytidine
Anorexia
drug toxicity
cytidine
Neutropenia
neutropenia
Half-Life
anorexia
High Pressure Liquid Chromatography
half life

Keywords

  • demethylating agent
  • DNA methylation
  • dog pharmacokinetics and toxicity
  • epigeneitcs
  • zebularine

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Fulkerson, C. M., Dhawan, D., Jones, D. R., Marquez, V. E., Jones, P. A., Wang, Z., ... Knapp, D. W. (2017). Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs. Veterinary and Comparative Oncology, 15(1), 226-236. https://doi.org/10.1111/vco.12159

Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs. / Fulkerson, C. M.; Dhawan, D.; Jones, D. R.; Marquez, V. E.; Jones, P. A.; Wang, Z.; Wu, Q.; Klaunig, J. E.; Fourez, L. M.; Bonney, P. L.; Knapp, D. W.

In: Veterinary and Comparative Oncology, Vol. 15, No. 1, 01.03.2017, p. 226-236.

Research output: Contribution to journalArticle

Fulkerson, CM, Dhawan, D, Jones, DR, Marquez, VE, Jones, PA, Wang, Z, Wu, Q, Klaunig, JE, Fourez, LM, Bonney, PL & Knapp, DW 2017, 'Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs', Veterinary and Comparative Oncology, vol. 15, no. 1, pp. 226-236. https://doi.org/10.1111/vco.12159
Fulkerson, C. M. ; Dhawan, D. ; Jones, D. R. ; Marquez, V. E. ; Jones, P. A. ; Wang, Z. ; Wu, Q. ; Klaunig, J. E. ; Fourez, L. M. ; Bonney, P. L. ; Knapp, D. W. / Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs. In: Veterinary and Comparative Oncology. 2017 ; Vol. 15, No. 1. pp. 226-236.
@article{b212bd0f05284459a246135e8e87506f,
title = "Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs",
abstract = "The purpose of this study was to determine the plasma pharmacokinetics (PK) and toxicity of zebularine, an oral cytidine analog with demethylating activity, in dogs. Plasma zebularine concentrations were determined by HPLC-MS/MS following an oral zebularine dose of 8 or 4 mg kg−1. Plasma zebularine clearance was constant. Mean maximum concentration (Cmax) was 23 ± 4.8 and 8.6 ± 1.4 µM following 8 and 4 mg kg−1, respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 following 8 and 4 mg kg−1, respectively. A single 8 mg kg−1 dose was well tolerated. Daily 4 mg kg−1 treatment in three laboratory dogs resulted in grade 4 neutropenia (n = 3), grade 1 anorexia (n = 2) and grade 1 or 2 dermatologic changes (n = 2). All adverse events resolved with supportive care. A 4 mg kg−1 dose every 21 days was well tolerated. A follow-up dose escalation study is in progress with a lower starting dose.",
keywords = "demethylating agent, DNA methylation, dog pharmacokinetics and toxicity, epigeneitcs, zebularine",
author = "Fulkerson, {C. M.} and D. Dhawan and Jones, {D. R.} and Marquez, {V. E.} and Jones, {P. A.} and Z. Wang and Q. Wu and Klaunig, {J. E.} and Fourez, {L. M.} and Bonney, {P. L.} and Knapp, {D. W.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/vco.12159",
language = "English (US)",
volume = "15",
pages = "226--236",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5810",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs

AU - Fulkerson, C. M.

AU - Dhawan, D.

AU - Jones, D. R.

AU - Marquez, V. E.

AU - Jones, P. A.

AU - Wang, Z.

AU - Wu, Q.

AU - Klaunig, J. E.

AU - Fourez, L. M.

AU - Bonney, P. L.

AU - Knapp, D. W.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The purpose of this study was to determine the plasma pharmacokinetics (PK) and toxicity of zebularine, an oral cytidine analog with demethylating activity, in dogs. Plasma zebularine concentrations were determined by HPLC-MS/MS following an oral zebularine dose of 8 or 4 mg kg−1. Plasma zebularine clearance was constant. Mean maximum concentration (Cmax) was 23 ± 4.8 and 8.6 ± 1.4 µM following 8 and 4 mg kg−1, respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 following 8 and 4 mg kg−1, respectively. A single 8 mg kg−1 dose was well tolerated. Daily 4 mg kg−1 treatment in three laboratory dogs resulted in grade 4 neutropenia (n = 3), grade 1 anorexia (n = 2) and grade 1 or 2 dermatologic changes (n = 2). All adverse events resolved with supportive care. A 4 mg kg−1 dose every 21 days was well tolerated. A follow-up dose escalation study is in progress with a lower starting dose.

AB - The purpose of this study was to determine the plasma pharmacokinetics (PK) and toxicity of zebularine, an oral cytidine analog with demethylating activity, in dogs. Plasma zebularine concentrations were determined by HPLC-MS/MS following an oral zebularine dose of 8 or 4 mg kg−1. Plasma zebularine clearance was constant. Mean maximum concentration (Cmax) was 23 ± 4.8 and 8.6 ± 1.4 µM following 8 and 4 mg kg−1, respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 following 8 and 4 mg kg−1, respectively. A single 8 mg kg−1 dose was well tolerated. Daily 4 mg kg−1 treatment in three laboratory dogs resulted in grade 4 neutropenia (n = 3), grade 1 anorexia (n = 2) and grade 1 or 2 dermatologic changes (n = 2). All adverse events resolved with supportive care. A 4 mg kg−1 dose every 21 days was well tolerated. A follow-up dose escalation study is in progress with a lower starting dose.

KW - demethylating agent

KW - DNA methylation

KW - dog pharmacokinetics and toxicity

KW - epigeneitcs

KW - zebularine

UR - http://www.scopus.com/inward/record.url?scp=85013979556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013979556&partnerID=8YFLogxK

U2 - 10.1111/vco.12159

DO - 10.1111/vco.12159

M3 - Article

C2 - 26178438

AN - SCOPUS:85013979556

VL - 15

SP - 226

EP - 236

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5810

IS - 1

ER -